The first clinical trials of CAR T cvells enrolled patients with CD19-positive hematological cancers, such as B-cell acute lymphoblastic leukemia (B-ALL) (197–199) or chronic lymphocytic leukemia (CLL) (200–203). The gene discussed is CD19; the disease is B-cell chronic lymphocytic leukemia.